

In a year that’s seen a sharp decline in initial public offerings, Washington, D.C.-based Mediterranean restaurant chain Cava Group (NYSE: CAVA) made a striking...
You can purchase shares of Cadrenal Therapeutics (NASDAQ:CVKD) through any online brokerage.
Other companies in Cadrenal Therapeutics’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
Cadrenal Therapeutics has a consensus price target of $36.50.
The stock price for Cadrenal Therapeutics (NASDAQ: CVKD) is $1.05 last updated November 5, 2026 at 11:42 AM EST.
There are no upcoming dividends for Cadrenal Therapeutics.
Cadrenal Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Cadrenal Therapeutics.
Cadrenal Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to...